N	Concordance
1	sponsiveness to adjuvant and palliative endocrine therapies. Presence of progest
2	rapy or the use of ablative or additive endocrine therapy to control disseminate
3	tive treatment  Relapsed after adjuvant endocrine therapy with an antiestrogen o
4	of concomitant or sequential chemo- and endocrine therapy has not been consisten
5	least 30 days since systemic anticancer endocrine therapy  Radiotherapy:   At le
6	given chemotherapy may not benefit from endocrine therapy administered secondari
7	rnative to tamoxifen for the first-line endocrine therapy of postmenopausal adva
8	anced breast cancer or as a second line endocrine therapy after the failure of l
9	e not randomly submitted to maintenance endocrine therapy (MET). Liver involveme
10	I patients were to receive preoperative endocrine therapy consisting of leuproli
11	ncept is the correlation of response to endocrine therapy with the presence or a